CTKB — Cytek Biosciences Income Statement
0.000.00%
Last trade - 00:00
- $774.48m
- $514.28m
- $193.02m
- 79
- 22
- 72
- 59
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | PROSPECTUS | PROSPECTUS | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 57.9 | 92.8 | 128 | 164 | 193 |
Cost of Revenue | |||||
Gross Profit | 28.7 | 51.7 | 79.1 | 101 | 109 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Total Operating Expenses | 75.1 | 79.2 | 119 | 166 | 221 |
Operating Profit | -17.3 | 13.7 | 9.16 | -1.8 | -27.8 |
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | -16.3 | 14.4 | 5.94 | 1.26 | -15.7 |
Provision for Income Taxes | |||||
Net Income After Taxes | -16.8 | 19.4 | 3.03 | 2.48 | -12.1 |
Minority Interest | |||||
Net Income Before Extraordinary Items | |||||
Net Income | -16.8 | 19.4 | 3 | 2.58 | -12.1 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Diluted Net Income | -16.8 | 3.22 | 0 | 2.58 | -12.1 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | -0.029 | 0.025 | 0.001 | 0.019 | -0.09 |
Dividends per Share |